FreeStyle Libre 14 day system

The first and only 14 day continuous glucose monitoring (CGM) solution clinically proven to reduce time spent in hypoglycemia.2,3

SIMPLE SYSTEM

Up to 14 days of sensor wear with a fast,
1-hour warm-up time

ACCURATE4 READINGS

The only CGM to maintain accuracy4 over 14 days without the need for fingerstick calibration or sensor coding||

MORE AFFORDABLE

Most commercially insured patients will pay between $10 and $75 per month#

See FreeStyle Libre Pro
PRODUCT OVERVIEW

FreeStyle Libre Pro:
Professional continuous glucose monitoring (CGM) made easy

FreeStyle Libre link
Reader stays in office
FreeStyle Libre link
No fingerstick calibration for patients
FreeStyle Libre link
Up to 14 days of glucose readings and patterns
FreeStyle Libre link
Reimbursable procedure with broad coverage††

See FreeStyle Libre 14 day
PRODUCT OVERVIEW

FreeStyle Libre link

Learn more about the new
FreeStyle Libre 14 day personal CGM system

FreeStyle Libre link

FreeStyle Libre 14 day system coverage information

FreeStyle Libre 14 day system is more affordable personal CGM for your patients

Have a sales representative tell you more

A rep can keep you informed about new and existing Abbott products

FreeStyle Libre link

*Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.

Based on a comparison of list prices of the FreeStyle Libre 14 day system versus competitors’ CGM systems. FreeStyle Libre 2 system will be list priced the same rate as FreeStyle Libre 14 day system. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

§LibreView is developed, distributed, and supported by Newyu, Inc. The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.

||Calibration or coding not required by the user.

Based on a comparison of list prices of the FreeStyle Libre 14 day system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

#Benefits of FreeStyle Libre 14 day sensors apply to two 14 day sensors per month. Benefits for FreeStyle Libre 14 day reader apply to one 14 day reader. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs, or residents of US territories and possessions, except Puerto Rico. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary. The FreeStyle Libre 14 day system requires a prescription.

**FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle LibreLink app requires registration with LibreView, a service provided by Abbott and Newyu, Inc.

††Coverage is limited to patients for whom professional CGM is medically necessary. Individual plan coverage may vary. Always verify coverage criteria and frequency directky with the payer.

References: 1. FreeStyle Libre 2 User's Manual. 2. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked randomised controlled trial. Lancet. 2016;388(10057):2254-2263. 3. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73. 4. FreeStyle Libre 14 day User's Manual.

ADC-12852 v7.0 06/20